Who Paid My Doc
Saxenda
Drug Obesity
NDC 0169-2800-15
General payments
$11,434,246
Research payments
$9,709,687
Through program year 2025, $11,434,246 in general payments and $9,709,687 in research payments were reported against Saxenda (Obesity).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $194,877 | 2,536 |
| 2025 | Research | $69,409 | 49 |
| 2024 | General | $140,856 | 3,441 |
| 2024 | Research | $416,808 | 328 |
| 2023 | General | $144,173 | 9,409 |
| 2023 | Research | $411,714 | 695 |
| 2022 | General | $4,436,490 | 64,711 |
| 2022 | Research | $457,333 | 1,086 |
| 2021 | General | $1,817,133 | 33,248 |
| 2021 | Research | $995,770 | 2,323 |
| 2020 | General | $1,813,969 | 30,178 |
| 2020 | Research | $3,274,575 | 84 |
| 2019 | General | $2,886,748 | 47,013 |
| 2019 | Research | $4,084,079 | 196 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 67 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
190,536 general · 4,761 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.